3 Ways to Invest in the Growing GLP-1 Weight Loss Market

Why It Matters

The rapid expansion of GLP‑1 therapeutics creates a high‑growth investment theme, and diversified vehicles now let investors capture upside while managing company‑specific risk.

Key Takeaways

• Structure Therapeutics holds $1.4 B cash for GLP‑1 development
• Aleniglipron achieved 16.3% weight loss in early trials
• Roundhill OZEM ETF returned ~45% YTD with active management
• THNR passive ETF tracks same universe, returned ~30% past year
• GLP‑1 market projected to reach $185 B by 2033

Pulse Analysis

The GLP‑1 receptor agonist market has become one of the fastest‑growing segments in pharmaceuticals, driven by soaring demand for weight‑loss solutions such as Novo Nordisk’s Ozempic and Wegovy. Analysts forecast a compound annual growth rate of about 12.4%, pushing total market size to roughly $185 billion by 2033. This expansion is not limited to the United States, but the U.S. remains the dominant consumer, offering investors a sizable domestic arena to target both established manufacturers and emerging biotech innovators.

Among the emerging players, Structure Therapeutics (NASDAQ: GPCR) stands out with its candidate aleniglipron, which has demonstrated a 16.3% average weight‑loss effect in early studies. The company’s robust balance sheet—approximately $1.4 billion in cash—provides a comfortable runway to advance the drug into a pivotal Phase 3 trial. While the stock is currently unprofitable, a consensus analyst price target of $110 implies potential upside exceeding 100% from current levels, making it a compelling direct exposure to the GLP‑1 wave.

For investors seeking broader, less company‑specific exposure, two ETFs have emerged. Roundhill’s GLP‑1 & Weight Loss ETF (OZEM) employs active management to concentrate on roughly two dozen pharma firms, delivering a 45% return over the past year despite a modest $53 million asset base. In contrast, Amplify’s THNR ETF offers a passive, market‑cap‑weighted approach with a similar universe but a smaller $4 million AUM, returning about 30% in the same period. Both funds charge a competitive 0.59% expense ratio, giving investors flexible pathways to ride the GLP‑1 growth story while balancing risk and cost considerations.